In 2022 the question was how fast developers could build. In 2026 it's which buildings deserve to exist. That shift, not the vacancy headline, is the real story.
NHRD Medical Real Estate | Advisory Perspective
A few years ago, the prevailing question in life sciences real estate was whether developers could build fast enough to keep up. Lab space in the top clusters was effectively sold out — vacancy in Boston and the San Francisco Bay Area sat below 5% — and life science facilities traded at roughly $645 per square foot, more than double the average office building. Capital poured in. Speculative towers rose on the assumption that demand was structural and inexhaustible.
It wasn't, at least not at that pace. The honest reckoning for 2026 is that the sector has been through one of the sharpest corrections in commercial real estate. But the "bust" framing that has replaced the "boom" framing is just as lazy as the euphoria it succeeded — and for owners, developers, and occupiers, just as misleading. What actually happened is more useful to understand.
From scarcity to glut, in three years
The drivers were a textbook supply-and-demand collision. An unprecedented construction wave — much of it speculative — delivered straight into a venture-funding pullback, higher interest rates, and, in 2025, federal headwinds: proposed NIH cuts, pharmaceutical tariffs, and "most favored nation" pricing pressure. Boston alone carried a record 17 million square feet of available lab space by mid-2025, much of it newly built and never leased. Nationally, analysts estimate the market needs 20–25 million square feet of absorption or removal to return to equilibrium.
That is a genuine glut. But the headline vacancy number conceals the more important fact: much of the empty inventory was never truly Class A to begin with. This is not simply too much space. It is too much of the wrong space — and that distinction is where the next decade will be won or lost.
Three structural shifts hiding behind the vacancy rate
1. Speculation is dead; conviction development is back. The era of building lab space on spec and trusting demand to appear is over. New construction has slowed to its lowest level since 2017, and what is breaking ground now is overwhelmingly build-to-suit or self-developed by pharma and biotech occupiers themselves. For developers, the discipline is unforgiving but clarifying: capital now follows a signed tenant, not a thesis.
2. The lab itself is being redesigned. AI and automation are quietly rewriting the physical program of a research building. As robotics and computation absorb work once done at the wet bench, AI-native biotechs are leasing roughly a third less space per employee than traditional firms and shifting toward a lab-to-office ratio closer to 45:55. These companies already represent about one in six biotech venture deals. The implication for real estate is profound: the building optimized for 2021 biology is not the building these tenants want, and a meaningful share of today's "obsolete" vacancy reflects design assumptions that aged in three years rather than thirty.
3. The capital base is rotating from startups to scale. As venture-backed leasing receded, global pharmaceutical companies stepped into the gap, accounting for their highest share of R&D leasing activity in recent memory. Pharma has pledged on the order of $475 billion toward U.S. manufacturing and R&D, accelerated by reshoring incentives, looming patent cliffs, and tariff exposure. The growth edge is migrating from early-stage lab demand in the big-three clusters toward later-stage R&D, cGMP manufacturing, and build-to-suit campuses — frequently in lower-cost, midsize, and Sun Belt markets that barely registered a decade ago.
The fundamentals never left
It would be a mistake to read the correction as a verdict on the underlying demand. U.S. life sciences employment hit a record 2.1 million in early 2025. R&D investment sales rebounded to roughly $13.5 billion in 2025, up nearly 30% year over year. Venture funding has stabilized, biotech equity valuations rallied in the second half of 2025, and 2025 produced a record class of innovative drug approvals. An aging population guarantees rising demand for therapies the industry exists to develop.
What changed is not whether the science needs space, but the discipline with which that space gets financed, designed, and located. JLL projects availability will grind back toward 20% by 2030 — driven not by a demand miracle but by supply rationalization, distress sales, and the conversion of perhaps 18–19 million square feet to other uses. In other words, the market heals primarily by removing the wrong buildings, not by filling them.
What it means for owners, developers, and occupiers
For owners and investors, the spread between prime and commodity assets is now the entire game. Well-located, genuinely Class A buildings will gain share; everything else faces re-tenanting risk, conversion economics, or distress. Underwriting must price that bifurcation explicitly rather than treating "life science" as a single asset class.
For developers, the opportunity has moved from building inventory to solving specific problems: build-to-suit for credit tenants, adaptive reuse of mispriced distressed assets, and purpose-built manufacturing in emerging markets where the reshoring capital is heading.
For occupiers, this is, for the first time in years, a tenant's market — falling rents, rising concessions, and leverage to secure space engineered for how research actually works today rather than how it worked at the last peak.
The boom of 2022 was real, but it was indiscriminate. What replaced it is harder, more selective, and ultimately healthier: a market that rewards the right building, in the right place, backed by the right tenant. That is not the end of the life sciences story. It is the sector growing up — and for those who underwrite it clearly, the most interesting chapter yet.
NHRD is a national healthcare and life sciences real estate consulting firm providing site selection, transaction advisory, design and construction oversight, development, financing, and program management for health systems, life science organizations, and investors. Contact us to discuss your life sciences real estate strategy.
Market figures reflect publicly reported data from CBRE, JLL, Cushman & Wakefield, Colliers, and PwC/ULI as of early 2026, and are subject to revision as conditions evolve.
Share:
